KBC Group’s Akero Therapeutics AKRO Stock Holding History

KBC Group’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,550	Closed	-$74K	–	1730
2025 Q3	$74K	Hold	1,550	–	–	﹤0.01%	1454
2025 Q2	$83K	Sell	1,550 -1,421	-48%	-$64.6K	﹤0.01%	1315
2025 Q1	$120K	Buy	+2,971	New	+$126K	﹤0.01%	1375
2024 Q2	–	Sell	-1,521	Closed	-$38K	–	1845
2024 Q1	$38K	Hold	1,521	–	–	﹤0.01%	1684
2023 Q4	$36K	Hold	1,521	–	–	﹤0.01%	1716
2023 Q3	$77K	Buy	+1,521	New	+$70.8K	﹤0.01%	1127

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

KBC Group's AKRO Position: Q4 2025 in Review

KBC Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,550 shares — an estimated $74K sold.

KBC Group first reported a position in AKRO in Q3 2023 and held it in 6 quarters. The position peaked at $120K in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

KBC Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
KBC Group sold 1,550 Akero Therapeutics shares in Q4 2025, an estimated $74K.
KBC Group first reported a position in Akero Therapeutics in Q3 2023 and held it in 6 quarters.
KBC Group's Akero Therapeutics position peaked at $120K in Q1 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on KBC Group's 13F filing for Q4 2025, filed 26 Jan 2026.